Abstract
This paper reviews some issues concerning comparison of pharmaceutical quality and bioequivalence between original drug products and their generics. A need for periodic routine monitoring of the currently marketed drug products and more stringent governmental control for quality of being approved drugs are also considered. Under current market glut in the pharmaceutical sector, the means of control through the additional drug quality assessment performed by independent institutes with appropriate facilities is proposed.
-
1.
Kelesidis T., Kelesidis I., Rafailidis P.I., et al. Counterfeit of substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemoter 2007; 60:214-36.
-
2.
Ламберт П.А., Конвей Б.Р. Сравнение фармацевтического качества генерических препаратов цефтриаксона и Роцефина. Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6:260-72.
-
3.
Белоусов Ю. Дженерики – мифы и реалии. Ремедиум 2003; 7-8:4-9.
-
4.
Вольская Е., Коковин Л. Сила и слабость дженериков: Российский рынок воспроизведенных препаратов. Ремедиум 2003; 7-8:10-13.
-
5.
Смоленов И.В., Красильникова А.В. Фармакоэкономические аспекты применения азитромицина различных производителей при внебольничной пневмонии у взрослых. Фарматека 2003; 13:78-87.
-
6.
Реестр зарегистрированных лекарственных средств. http://www.regmed.ru
-
7.
Meos A., Gvozdev D. Comparative study of ciprofloxacin tablets registered in Estonia to those produced in Russian Federation. 6th World meeting on pharmaceutics, biopharmaceutics and pharmaceutical technology, 7-10 April 2008, Barcelona, Spain.